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Abstract
Background: The purpose of this study was to define an optimal injection protocol for 5–10 min duration
navigator-based coronary MR angiography using an intravascular gadolinium-based contrast agent (GBCA),
which is better suited for steady-state coronary MR angiography than conventional GBCAs.
Methods: Using projections from pharmacokinetic models of the intravascular concentration of gadofosveset,
a dual-injection protocol was formulated and tested on 14 healthy human subjects. Modified Look-Locker
inversion recovery (MOLLI) sequences were used for T1 mapping at 3 Tesla to evaluate the concentration of
tracer in the aorta over the scanning interval.
Results: Pharmacokinetic models for a bolus plus slow infusion technique at a 5, 10, and 15 min steady
state intravascular concentration was compared to single bolus curves. The 70 %/30 % bolus/slow infusion
technique resulted in the highest intravascular concentration over a 5 min scan duration. Similarly, the
60 %/40 % bolus/slow infusion technique was projected to be ideal for image acquisition duration of
5–10 min. These models were confirmed with T1 maps on normal volunteers. Arterial-venous mixing of
contrast was achieved within 90 s of the beginning of the bolus.
Conclusions: Gadofosveset injection is optimized for the lowest intravascular T1 time for 5–10 min duration
MR angiography by bolus injection of 60–70 % of the total dose followed by slow infusion of the remainder
of the total dose. This protocol achieves rapid and prolonged steady state intravascular concentrations of the
GBCA that may be useful for prolonged image acquisition, such as required for navigator-based coronary MR
angiography at 3 Tesla.
Trial registration: ClinicalTrials.gov identifier: NCT01130545NCT01130545, registered as of May 25, 2010.
Keywords: Gadofosveset trisodium, MS-325, Gadolinium-based intravascular contrast agent, Whole-heart
coronary magnetic resonance angiography, Navigator-based angiography, 3.0 Tesla, Image quality, Respiratory
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Background
Although 3.0 Tesla (3T) magnetic resonance angiog-
raphy (MRA) can be achieved during a breath-hold
with administration of a GBCA, very high-resolution
images of coronary or other vessels are not readily
accomplished within a breath-hold. Thus, navigator
based coronary MRA has been developed [1]. Acqui-
sition time with navigator based MRA is can be high
(>10 min), depending on the efficiency of the naviga-
tor sequence (typically 30–50 %).
For coronary artery imaging at 3T, the balanced
steady-state free precession (bSSFP) technique is less ro-
bust and the overall contrast to noise ratio advantage
over 1.5 Tesla is diminished [2]. As an alternative, the
success of contrast enhanced coronary angiography at
3T had been demonstrated [3] and the addition of 3D
non-Cartesian acquisition with 100 % imaging efficiency
can reduce imaging time to less than 10 min [4–6].
However even this shorter acquisition time is much
longer than the intravascular residence time of common
GBCAs [7]. Following bolus injection, extracellular
distribution of common GBCAs results in rapid loss of
vascular signal and diminished contrast to noise ratio
due to enhancement of surrounding structures [7, 8].
Compared to other GBCAs, Gadofosveset (Ablavar®,
Lantheus Medical Imaging, North Billerica, MA, USA)
has a high intravascular residence time due to albumin
binding compared to other GBCAs [9], which is theoret-
ically well suited for this application. Gadofosveset and
gadobenate (MultiHance®, Bracco Diagnostic Inc., Sin-
gen, Germany) have previously been compared for myo-
cardial enhancement using a slow infusion technique
[10], and coronary MRA with gadofosveset has been
studied using navigator-based approaches using a single
bolus injection [8]. Owing to work investigating alternate
infusion techniques with GBCAs with low intravascular
residence time [11], the same techniques have not been
investigated with gadofosveset, which may be further
optimized by a dual injection technique rather than with
a single bolus infusion.
The purpose of this study was to determine the
parameters for a dual injection protocol for gadofosveset
to achieve a steady intravascular T1 signal in vivo in
order to optimize imaging for MR acquisition times
under 10–15 min, such as with whole-heart coronary
MRA at 3T [8, 12–14]. In this study, we performed
pharmacokinetic simulations of gadofosveset followed by




This study was conducted at the Clinical Center at the
National Institutes of Health (Bethesda, Maryland, United
States). The National Heart, Lung, and Blood Institute re-
view board approved the study and informed consent was
obtained from all study participants (ClinicalTrials.gov
Identifier: NCT01130545). Fourteen eligible subjects were
<50 years of age, and were without cardiovascular, renal,
or liver disease. Standard exclusion criteria included me-
tallic implants, claustrophobia, impaired glomerular filtra-
tion, or any condition or situation that precluded the
safety of MR scanning. Weight, height, and heart rate were
recorded for all subjects at the time of imaging, as well as
serum creatinine and blood pressure. Glomerular filtration
rate and body mass index were calculated. Subjects were re-
cruited within a 6-month time period and were permitted
to have initial or repeat scanning in the absence of MR con-
trast administration within the last 30 days.
Pharmacokinetic modeling
Gadofosveset plasma concentrations vs. time profiles
were simulated using WinNonlin pharmacokinetic soft-
ware, version 5.0 (Pharsight Corporation, Mountain
View, CA, USA). Using a 100 % bolus (no slow infusion
phase) as a reference, simulated pharmacokinetic data
were systematically assessed for their ability to maintain
relatively constant gadofosveset plasma concentrations
for a 5, 10, and 15 min durations with a bolus followed
by a slow infusion phase. Simulations were conducted
using initial pharmacokinetic parameter estimates that
were based upon the biphasic nature (two compartment
open model) of contrast disposition reported in the
manufacturer’s prescribing information for gadofosveset.
The simulation parameters sought to achieve a steady
state T1 of the vascular compartment of less than
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In equation (1), pre-contrast T1 (T1pre) at 3 T in the
blood was assumed to be 1664 ms [15]. The relaxivity
(r1) of gadofosveset is 9.9 (mmol.s)
−1 at 3 T in blood
plasma [16]. [Cb] refers to the contrast concentration in
blood. [Cb] = [Cp] × (1-[Hct]) where [Hct] refers to the
hematocrit which was assumed to be 40 % while [Cp] is
contrast concentration in plasma. Using equation 1,
post-contrast blood T1 values were calculated for refer-
ence to the experimentally determined plots and to the
in vivo behavior of the agent.
The gadofosveset vial injection concentration was
0.25 mmol/mL. Dilution of the agent with normal saline
to a final volume of 50 mL was intended to standardize
and simplify the preparation of the injection protocol.
This volume was used for both bolus and slow injection
phases; therefore, the final concentration was variable
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according to the prescribed weight-based dose. The
bolus phase of administration was set to a maximum of
1.5 mL/s. The lower limit of the slow infusion rate was
set by the MRI power injector and was 0.04 mL/s.
The time required for arterial-venous mixing coupled
with the time required for bolus contrast injection could
not be accurately modeled by pharmacokinetic software
because of the expected inter-subject physiologic vari-
ation. Therefore, the assumption of immediate injection
and equilibrium were required to limit computation to
the two-compartment model, requiring further evalu-
ation of the in vivo behavior at these phases.
In vivo evaluation
We sought to optimize injection parameters for MRA
duration of 5–10 min In vivo. Human testing was per-
formed using parameters derived from the pharmaco-
kinetic simulations (70 %/30 % n = 14 and 60 %/40 %
n = 5), and was compared to the in vivo behavior of a
baseline single (100 %, n = 3) bolus protocol. Injection
protocols were programmed on a Spectris Solaris EP
(MEDRAD Inc., Pittsburgh, Pennsylvania, USA) MR
compatible power injector. Following standard localizer
sequences and injection of gadofosveset, a 4-chamber,
single-slice, 11-heart beat modified Look-Locker inversion
recovery (MOLLI) sequence was acquired at 45–60 s
intervals during a breath hold on a 3T Verio (Siemens
Medical Solutions, Erlangen, Germany) using body matrix
coils [17]. MOLLI parameters included TR/TE 2.4/
1.03 ms; flip angle 35°; TI >125 ms with 80 ms increment;
1002 Hz bandwidth per pixel. Eight images of differing
inversion times were acquired with these parameters
for a single slice using generalized auto-calibrating
partially parallel acquisitions (GRAPPA) factor of 2.
Prospective ECG triggering was used for imaging the
heart at end diastole.
Image processing and analysis
The gadolinium concentration of the aorta was taken
to be similar to the coronary arteries but more accur-
ately determined due to larger size, and did not carry
the risk of measurement of trabeculations, as would
be the case for ventricular lumen measurement.
MOLLI sequences were used to form T1 maps to
measure absolute T1 times in the descending aorta
using the program QMass MR ver 7.2 (Medis, Raleigh,
North Carolina, USA) using regions of interest shown
in Fig. 1. Plots of time versus T1 values were used to
determine the time to achieve steady state T1 time,
and a consensus of 2 reviewers was used to record the
time of equilibrium for each scanning instance.
Percent change in T1 time from the point of early
equilibrium and 5 and 15 min thereafter was recorded,
with the intent to maintain T1 time deviation to less
than 10 % over intended scan durations. Percent
deviation in T1 time and following equilibrium is
expressed as the mean with the min-max range, and
other metrics are reported as the mean ± the standard
deviation. Mann-Whitney testing was used to measure
difference in median T1 time over a given scanning
interval between predicted and in vivo measurements
following equilibrium, with a p <0.05 for significance.
Results
Pharmacokinetic modeling
Shown in Fig. 2, the baseline model was 100 % bolus
infusion at 1.5 mL/s for gadofosveset dose of 0.12 mL/kg
or 0.03 mmol/kg (8.4 mL for a 70 kg subject, approxi-
mately 11 s infusion). Using the 100 % bolus approach,
blood concentration of gadofosveset was predicted to
drop rapidly to 40 % (Fig. 2, 1 min after equilibrium) of
maximum after the initial peak vascular concentration.
This was followed by a plateau phase beginning about
1 min after the beginning of the infusion (Fig. 2, “100 %
bolus” curve), where T1 time increased to more than
than 10 % of its baseline equilibrium value for a theoret-
ical 5-minute scan duration.
Administration of 70 % of the total gadofosveset dose
as a bolus (1.5 mL/s) followed by 30 % of dose adminis-
tered as a slow infusion (0.04 mL/s) showed approxi-
mately 5 min duration of a relatively high intravascular
gadofosveset concentration (approximately 70 % of the
100 % bolus curve) (Fig. 2, 5 min - 70 %/30 % protocol).
Targeted to achieve a constant concentration of
gadofosveset over 10 min, a 60 %/40 % (bolus/slow in-
fusion) dosing split showed low variation in intravas-
cular gadofosveset concentration; however, predicted
overall concentrations were lower with this approach
(0.63–0.68 mmol/L).
For a 15-minute scan duration, a 55 %/45 % (bolus/infu-
sion) dosing split predicted the least variability in intravas-
cular gadofosveset concentration. Overall concentrations
were lower with this approach (0.53–0.56 mmol/L), which
were insufficient compared to 70 %/30 % and 60 %/40 %
protocols, and were therefore not tested in vivo.
In vivo evaluation
Subject characteristics are shown in Table 1. Gadofosveset
dosing was calculated using the subject’s body weight at
time of scanning. Twenty-two scanning instances were
accomplished with 14 volunteers.
As predicted by pharmacokinetic modeling (Fig. 3),
the 100 % bolus (n = 3) had a lower T1 time initially but
the change in T1 time was more than 10 % between
arterial-venous equilibrium and 5 min thereafter. The
average time of arterial-venous equilibrium was 79 s
(71–94 min-max). Average T1 time over specific scan
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durations was not calculated because of the high degree
of T1 deviation following equilibrium.
For the 70 %/30 % (n = 14) injection protocol designed
to maintain up to 5 min steady state intravascular concen-
tration, there was also a rapid dip in T1 time, followed by
an average equilibrium time of 83 s (63–93 min-max). It
was observed that the steady-state was maintained to
sufficiently include a 5-minute scan duration following
equilibrium with an average of 5.2 % (0.26–9.7 % min-
max) variation in blood T1 time up to 7.5 min post
equilibrium. Average T1 time during the 5-minute post-
equilibrium scan duration was 269.9 ms ± 13.3, which
differed from the predicted average T1 time of approxi-
mately 189.1 ± 1.5 (P <0.001).
For the 60 %/40 % protocol (n = 5) designed for a
5–10 min duration acquisition time, average equilibrium
was reached at 85 s (66–95 min-max) and average change
in T1 was under 10 % (2.3 % mean, 0.5–6.7 % min-max)
up to 11.5 min following equilibrium. Average T1 time
during the 10-minute post-equilibrium scan duration was
289.0 ms ± 9.0, which was higher than the predicted aver-
age T1 time of approximately 225.3 ms ± 4.8 (P <0.001).
In aggregate, 90 s was considered an acceptable
estimate of the earliest appropriate time point of equilib-
rium for 100 %, 70 %/30 %, or 60 %/40 % injection pro-
tocols. Mean aortic pre-contrast T1 time was 1673 msec
(1604–1743 95 % confidence interval) for all scanning
instances, similar to the reported value of 1664 in the
literature [15]. It is noted that the aggregate curves
(Fig. 3d) for the sample are expected to appear more
variable than intra-subject steady-state concentrations
(Fig. 3a-c).
Discussion
Using T1 mapping, the goal of this study was to evaluate
the in vivo intravascular concentration of gadofosveset
using bolus and dual injection techniques for variable
time durations. There is recent interest in using gadofos-
veset for angiography at 3T [12–14, 18] which could
improve contrast and signal in the coronary arteries
compared to traditional GBCAs, which show compar-
ably rapid loss of vascular signal at even limited scan
durations (5–7 min). As predicted by mathematical
modeling, the use of a dual injection technique with
gadofosveset maintains a more stable intravascular
concentration compared to the admittedly more simple
single bolus technique. However, with the recent
advances in coronary MRA using model-based recon-
struction with 100 % imaging efficiency, scan duration
can potentially be reduced to within 3–7 min [4–6].
These methods rely on a posteriori motion compensa-
tion techniques which benefit from high signal and
contrast for non-rigid image-based registration [6]. With
these goals, we used simulated pharmacokinetic data to
predict the steady-state concentration-vs.time profile of
MR contrast in humans. Specifically, we show the in
vivo intravascular behavior of a dual injection technique
for gadofosveset. Its most immediate application may be
Fig. 1 Example of axial MOLLI images acquired of the heart. T1 time (in milliseconds) were derived from T1 maps using the MOLLI pulse sequence in
the descending aorta (DAo, white arrow) before injection and at subsequent time points after injection. MOLLI – modified Look-Locker
inversion recovery, LV left ventricle, RV right ventricle, RA right atrium, DAo descending aorta
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for coronary MRA [19]; however these methods are not
exclusive to the anatomy studied, and may apply to
other organs of interest. With proof-of-concept for the
injection scheme, we offer an inclusive template for
future steady-state intravascular concentrations for
immediate or unanticipated applicability for contrast
enhanced MRI. These findings may expand upon work
focused on the newer contrast agent gadofosveset for
cardiovascular applications such as myocardial T1 relax-
ation times and myocardial extracellular volume fraction
calculations [20, 21].
Our experience with this injection scheme led us to
make certain suggestions for accurate injection technique
when using a dual-injector that uses the same line for
saline and contrast (described in the Results section).
Specifically, our technique is designed to achieve a num-
ber of goals: (1) Maximize subject comfort and safety; (2)
Maximize injection accuracy; (3) Minimize contrast waste;
(4) Minimize complexity; (5) Minimize setup time; (6)
Maximize applicability to other injector types across
institutions.
To the extent that the temporal resolution of an 11
heartbeat, breath-hold MOLLI sequence (1 scan every
40–60s) can determine, the earliest time point after
bolus to begin scanning is suggested here. At approxi-
mately 90 s, steady state intravascular contrast con-
centrations should be sufficient for gadofosveset using
dual-injection techniques.
The study was only focused on the intravascular
concentration of contrast rather than addressing changes
in the extravascular state. Once stable intravascular
contrast concentrations are met, it may be possible to
attain a more rigorous understanding of variations in
extracellular flux of gadofosveset over the time of
infusion and thereafter.
Regarding limitations of our study, we used 3T field
strength and all scans used only healthy subjects. Our in
vivo measurements demonstrated significantly higher
average T1 time than the predicted pharmacokinetic
model for scan durations of interest, which is likely in
part due to the model’s inability to account for the time
required for injection and arterial-venous equilibrium.
This work was limited to the technical application of a
dual-injection procedure and was not designed to sys-
tematically measure differences in diagnostic image
quality. Although prediction of the absolute value of T1
time was not part of the research goal, the average pre-
contrast T1 times in blood for our sample was comparable
to that reported in the literature (1673 vs 1664, respect-
ively). We cannot exclude a small amount of systematic
Table 1 Subject demographics
Demographics
Age (years) 34.0 ± 7.1
Male n (%) 5 (36 %)
Height (m) 1.7 ± 0.1
Weight (kg) 71.9 ± 14.1
Body mass index (kg/m2) 23.6 ± 2.6
Hematocrit (%) 44.0 ± 3.3
Creatine (mg/dL) 0.88 ± 0.17
GFRa (mL/min/1.73 m2) 104.0 ± 15.3
Heart rate (bpm) 65.4 ± 3.9
Systolic blood pressure (mmHg) 118.8 ± 6.8
Diastolic blood pressure (mmHg) 69.0 ± 9.0
Contrast administration
Dose (mL) 9.0 ± 2.1
aGFR was calculated using the chronic kidney disease epidemiology
collaboration (CKD-EPI) formula. Because subjects could be imaged more than
once; age, gender, and height were calculated once, whereas other
measurements were calculated per imaging visit
GFR glomerular filtration rate
Fig. 2 Pharmacokinetic model for the intravascular concentration of
gadofosveset. Using various dual injection techniques, a fixed
percentage of the total volume is injected as the bolus phase,
followed by remainder as a slow infusion over a targeted duration to
maintain a steady state concentration. A 100 % bolus is also plotted for
reference. The 2-compartment model assumes immediate injection
and arterial-venous mixing (equilibrium)
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bias, which may explain some of the differences in
predicted T1 times compared to those measured in vivo.
If lower T1 times approaching values below 200 ms for
coronary artery MRA are desired, higher doses of gadofos-
veset may be required, which may warrant further investi-
gation. The sample sizes for the 60 %/40 % and 100 %
injection protocols were not as extensive as the 70 %30 %
injection scheme in order to maximize evaluation of the
more promising injection protocol (70 %/30 %), as
predicted by pharmacokinetic modeling. Likely sufficient
for proof-of-concept, this low sample size limited more
broad sub-sample experimentation. Retrospectively, we
observe that the injection of the entire contrast dose as a
bolus may result in a comparably low intravascular
concentration (Fig. 3d, 100 % curve) within 2–3 min after
equilibrium compared to the other injection schemes.
Although, we point out that it does so at the cost of the
stability of concentration, we acknowledge that the
bolus technique may be sufficient for image acquisi-
tion that does not require concentration stability. In
these regards, further study would likely be required
to compare objective measures of image quality in
healthy and disease states.
Conclusions
Pharmacokinetic simulation of gadofosveset intravascu-
lar concentration was exploited to formulate a dosing
approach that optimized the imaging capabilities of this
agent. We described a dual-injection technique, in which
an initial gadofosveset bolus was followed by a slow
infusion. This technique allowed for the rapid achieve-
ment of steady state intravascular gadofosveset concen-
trations, which remained stable for multiple scanning
durations (5 and 10 min). Using this model, we provide
proof-of-concept evidence in support of our injection
technique in humans.
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